Raj Panjabi was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
Past successes by trailblazers in other biotechnological fields could assist potential patentees navigate legal bumps along the road to IP protection for CRISPR-related inventions, as Patricia Carson and Ashley Ross of Kirkland & Ellis describe.
Fake pharmaceuticals not only harm innovators, they can have tragic consequences, and require a robust response from the authorities. LSIPR assesses how officials, particularly in South America, are responding to the threat.
With the PTAB facing questions over its authority and even constitutionality, life sciences companies seem to be faring well, at least compared to other industries, as LSIPR finds out.
Following the signing of a historic trade agreement with the EU, Canada now has a system of patent term extension. LSIPR considers the impact for pharmaceutical patentees.
CRISPR offers ground-breaking opportunities for tackling diseases and genome defects, but its use must be carefully managed to avoid the obvious ethical problems that will arise, as Sanchith Shivakumar of Anand and Anand reports.
Owners of biotech inventions may find Mexico an attractive country in which to apply for patent protection because of its non-restrictive patent law and its practical approach to examination, as Eder Gutiérrez of Clarke Modet & Co outlines.
Those working in the field of genetic sequence must clearly understand the subtleties of sequence searching, in order to avoid the risks of infringement and invalidity, as Ellen Sherin of GQ Life Sciences finds out.
Samantha Salim and Kene Gallois of Daniel Legal & IP Strategy investigate how Brazil’s patent office and health regulatory agency are coping with the complicated examination of pharmaceutical patent applications.
If biotech companies in Brazil understand that they can use both plant variety and patent protection in certain cases, their ability to innovate may improve, says Gabriel Di Blasi of Di Blasi, Parente & Associados.